• Present Job：
• Aug. 2018-Now Director of Master’s program, Graduate Institute of Medicine, Kaohsiung Medical University (KMU).
• Aug. 2017-Now Professor, Graduate Institute of Medicine, Kaohsiung Medical University (KMU).
• Aug. 2019-Now Voice CEO, Center of Applied Genomics, Kaohsiung Medical University (KMU)

1. Development Biology   
2. Gene transcription and Regulation  
3. Molecular oncology
4. Immunotherapy

1. Hepatology
2. Oncogene
3. Cell Death & Disease
4. Molecular therapy
5. Cancers
6. Biomedicines

1. Pharmaceutical composition of regulating the expression level of survival of motor neuron 1 and method of detecting enzyme activity of ubiquitin carboxyl-terminal hrdrolase L1 in human fibroblasts TW:100104844; US:13/032846.
2. Method of regulating the expression level of survival of motor neuron 1. US 9,045,793B2. (2015.06.09)
3. 104015-TW, 105T-11-052-080.
4. 107020-TW (I723562): MICE MODEL FOR LIVER PATHOLOGICAL CHANGES AND USE THEREOF.

1. 1. 1. 1. 2000. Excellent Poster Award, 8^th Symposium on Recent Advences in Cellular and Molecular Biology.
         2. 2001. Excellent Poster Award, 9^th Symposium on Recent Advences in Cellular and Molecular Biology.
         3. 2007. Excellent Poster Award, 15^th Symposium on Recent Advences in Cellular and Molecular Biology.
         4. 2010. Excellent Poster Award, 25^th Symposium on Recent Advences in Cellular and Molecular Biology.
         5. 2011. Outstanding Research award, Kaohsiung Medical University.
         6. 2013-2014. Travel Grant award, 72^nd -73^rd Annual Meeting of The Japanese Cancer Association (JCA).
         7. 2013-2014. Outstanding Research award, Kaohsiung Medical University
         8. 2014 Liver Disease Prevention Research Foundation Fellowship.
         9. 2018-2021. Outstanding Research award, Kaohsiung Medical University.
         10. 2018. Annual excellent research project funding, Kaohsiung Medical University.
         11. 2018, 2120-2022 Special Outstanding Talents of the Ministry of Science and Technology Awards, Ministry of Science and Technology, R.O.C., Taiwan.
         12. 2022, Dr. Tung Ta-Cheng’s Basic Cancer Research Award.

1. Li-Ting Wang, Kwei-Yan Liu , Shyh-Shin Chiou, Shau-Ku Huang, Shih-Hsien Hsu*, Shen-Nien Wang*. Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance. Cancer letters Cancer Lett. 2021 Jul 12; 520: 160-171.
2. Chuang KT, Wang SN, Hsu SH, Wang LT. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity. Cancer Med. 2021 Aug;10(16):5545-5556.
3. Li-Ting Wang#, Ming-Hong Lin#, Kwei-Yan Liu, Shyh-Shin Chiou, Shen-Nien Wang, Chee-Yin Chai, Li-Wen Tseng, Hsin-Ying Clair Chiou, Hsueh-Chun Wang, Kazunari K. Yokoyama, Shih-Hsien Hsu*, Shau-Ku Huang*. WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism. Autophagy. 2021 Dec;17(12):4202-4217.
4. Kwei-Yan Liu, Li-Ting Wang, Hsueh-Chun Wang, Shen-Nien Wang, Li-Wen Tseng, Chee-Yin Chai, Shyh-Shin Chiou, Shau-Ku Huang*, Shih-Hsien Hsu*. Aryl Hydrocarbon Receptor is Essential in the Control of Lung Club Cell Homeostasis. 2021 Jan. Journal of Inflammation Research 2021 Feb 5;14:299-311.
5. Wang LT, Liu KY, Jeng WY, Chiang CM, Chai CY, Chiou SS, Huang MS, Yokoyama KK, Wang SN, Huang SK, Hsu SH*. PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition. EMBO Rep. 2020 Feb 5;21(2):e48795. Highlighted by scrolling marquee of EMBO Reports.
6. Liu KY, Wang LT, Hsu SH*, Wang SN*. Homeobox Genes and Hepatocellular Carcinoma. Cancers (Basel). 2019 May 3;11(5). pii: E621. (Invited review)
7. Wang LT, Wang SN, Chiou SS, Liu KY, Chai CY, Chiang CM, Huang SK, Yokoyama KK, Hsu SH*. TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. Oncogene. 2019 Jan;38(4):518-532. doi: 10.1038/s41388-018-0457-z. [Epub ahead of print]
8. Chiu YH#, Hsu SH#, Hsu HW, Huang KC, Liu W, Wu CY, Huang WP, Chen JY, Chen BH, Chiu CC. Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. Int J Oncol. 2018 Nov;53(5):1967-1979. (# equal contribute to this manuscript)
9. Wang HC, Wong TH, Wang LT, Su HH, Yu HY, Wu AH, Lin YC, Chen HL, Suen JL, Hsu SH, Chen LC, Zhou Y, Huang SK. Aryl hydrocarbon receptor signaling promotes ORMDL3-dependent generation of sphingosine-1-phosphate by inhibiting sphingosine-1-phosphate lyase. Cell Mol Immunol. 2018 Mar 23. doi: 10.1038/s41423-018-0022-2.
10. Liu KY, Wang LT, Hsu SH*. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma. Cancers (Basel). 2018 Jan 3;10(1). pii: E8. (Invited review)
11. Wang YS, Hsi E, Cheng HY, Hsu SH, Liao YC, Juo SH. Let-7g suppresses both canonical and non-canonical NF-κB pathways in macrophages leading to anti-atherosclerosis. Oncotarget. 2017 May 23. doi: 10.18632/oncotarget.18197.
12. Li-Ting Wang, Shyh-Shin Chiou, Chee-Yin Chai, Edward Hsi, Kazunari K. Yokoyama, Shen-Nien Wang, Shau-Ku Huang, Shih-Hsien Hsu*. Intestine-specific homeobox gene ISX integrates interleukin-6 signaling, tryptophan metabolism, and immune suppression. Cancer Research. 2017 Aug 1;77(15):4065-4077.
13. Hsu SH*, Wang LT, Chai CY, Wu CC, Hsi E, Chiou SS, Wang SN. Aryl hydrocarbon receptor promotes hepatocellular carcinoma tumorigenesis by targeting intestine-specific homeobox expression. Mol Carcinog. 2017 Oct;56(10):2167-2177.
14. Wang LT, Chiou SS, Chai CY, Hsi E, Chiang CM, Huang SK, Wang SN, Yokoyama KK, Hsu SH*. Transcription factor SPZ1 promotes TWIST-mediated epithelial- mesenchymal transition and oncogenesis in human liver cancer. Oncogene. 2017 Aug;36(31):4405-4414.
15. Wang LT, Chiou SS, Chai CY, Hsi E, Wang SN, Huang SK, Hsu SH*. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma. Oncotarget. 2017 Jan 31;8(5): 7489-7501.
16. Chen CY, Yen CY, Wang HR, Yang HP, Tang JY, Huang HW, Hsu SH*, Chang HW*. Tenuifolide B from Cinnamomum tenuifolium Stem Selectively Inhibits Proliferation of Oral Cancer Cells via Apoptosis, ROS Generation, Mitochondrial Depolarization, and DNA Damage. Toxins (Basel). 2016 Nov 5;8(11).
17. Wang SN, Wang LT, Sun DP, Chai CY, Hsi E, Kuo HT, Yokoyama KK, Hsu SH*. Intestine-specific homeobox (ISX) upregulates E2F1 expression and related oncogenic activities in HCC. Oncotarget. 2016 Jun 14;7(24):36924-36939.
18. Chen WC, Tseng CK, Chen YH, Lin CK, Hsu SH, Wang SN, Lee JC*. HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway. PLoS One. 2015 Jul 31;10(7):e0133264.
19. Shyh-Shin Chiou; Li-Ting Wang; Shih-Bo Huang; Chee-Yin Chai; Shen-Nien Wang; Yu-Mei Liao; Pei-Chin Lin; Kwei-Yan Liu; Shih-Hsien Hsu*. Wntless (GPR177) expression correlates with poor prognosis in B-cell precursor acute lymphoblastic leukemia via Wnt signaling. Carcinogenesis 2014 35 (10):2357-2364.
20. Li-Ting Wang, Shyh-Shin Chiou, Yu-Mei Liao, Yuh-Jyh Jong, Shih-Hsien Hsu* Survival of motor neuron protein downregulates miR-9 expression in patients with spinal muscular atrophy. Kaohsiung Journal of Medical Sciences 2014 (30), 229-234.

❖ Biography:                                                                              ⎢View full profile ⎢
   Dr. Sen-Yung Hsieh earned his M.D. degree from the National Yang Ming University, and Ph.D. in Molecular Virology from the University of Pennsylvania (sponsored by a government scholarship). He then completed his clinical training in internal medicine with a specialty in hepato-gastroenterology in Chang Gung Memorial Hospital (CGMH), Linkou, Taiwan. Currently, he is Professor of Medicine and Microbiology and Immunology at the Chang Gung University (CGU) and Professor of Internal Medicine and Hepato-Gastroenterology at CGMH (since 2005). He was entitled to establish the Clinical Proteomics Lab at CGMH in 2003. He was the former Director of Department of Medical Research of the hospital from 2010 to 2016. Under the supervision of the CGMH foundation leadership, he had led a multidisciplinary team designing and constructing the new research building for the hospital (2010-2017). He is now the head of the Department of Gastroenterology and Hepatology, Linkou CGMH.
   He initially focused on the molecular virology and epidemiology of human hepatitis viruses. His team for the first time identified the zoonotic transmission of hepatitis E virus from pigs to humans in 1998. Since 2010 pigs have been proven as the primary transmitting source of acute hepatitis E, which leads to more than 100,000 cases each year in Europe. Currently, Dr. Hsieh is interested in elucidation the molecular mechanisms involving in carcinogenesis of human hepatoma. By integration of genomics, proteomics, functional genomics and mol and cellular biology approaches, he has identified several novel genes and pathways that play significant roles in the oncogenesis of human hepatoma. He discovered the Her2/Her3—Neuregulin autocrine loop in human hepatoma cells, which contributes to tumor invasion and metastasis and is involved in resistance to EGFR-targeted therapies in some of the human cancers. Recently, his group unveiled the mystery of how large tumors tend to invade and disseminate systemically. He found that actin cytoskeleton remodeling induced by intrinsic or microenvironmental cues can drive EMT reprogramming via induction of HIF and NOTCH signaling in a cell-density-dependent manner. Dr. Hsieh sought to elucidate the reason why the hepatoma incidence in Taiwan (35/100,000) is much higher than in other viral hepatitis prevalent countries in the world. Via a collaboration with Dr. BT Teh and Dr. Steven Rozen at the National Singapore University, he found that 78% (77/98) of HCCs contain aristolochic acid (AA) mutational signature, highest in the world (China, 47%; Korea, 13%; Japan, 2.7%; North America, 5%; Europe, 2%; Ng et al., Sci Transl Med, 2017). AA, present in some TCM and herbs, is most mutagenic to humans and related to many urinary tract cancers. These findings indicate widespread use of AA-containing TCM or remedies in our patients with chronic liver disease, which further promotes tumor development. Dr. Hsieh hopes to use this objective scientific evidence to urge patients with chronic hepatitis and cirrhosis to follow the physician's instructions but not take any folk remedies. His studies have been recognized by many domestic and international academic societies, including Outstanding Research Awards from Prof Song JL foundation (1994), Taiwan Medical Association (1999), Jap Soci Liver Study (2002), Chang Gung University (2013), Ministry of Science and Technology Outstanding Research Award (2017), Dr. Ta-Cheng Tung’s Basic Cancer Research Award (2018), and American Association for Cancer Research (AACR Team Science Award, 2018).

❖ General Profile:            ⎢View full profile⎢Linkedin profile⎢Lab Webpage⎢
Dr. Tsai is a rigorously trained physician-scientist focusing on basic and translational research in cancer. He specializes in tumor epigenetics, tissue architecture, therapeutic resistance and cancer stemness, with a career goal aiming at targeting and treating metastasis and treatment resistance, the two major reasons for cancer mortality. Dr. Tsai graduated with a MD in 1993 from Taipei Medical University, Taiwan, and completed his clinical training and was board certified in internal medicine, gastroenterology and GI oncology. Dr. Tsai earned his PhD in 2005 in Genetics and Complex Diseases from Harvard University, USA. During his PhD work Dr. Tsai established novel three-dimensional coculture models to interrogate stromal-epithelial interactions. In 2007, he joined Valerie M. Weaver's Laboratory at UCSF to study a novel epigenetic mechanism in cancer drug resistance. Following his postdoc research Dr. Tsai funded the Laboratories for Tumor Aggressiveness and Stemness (The TAS Lab) and rose to the Associate Investigator at National Institute of Cancer Research in National Health Research Institutes, Taiwan. He has published first or corresponding author papers in top-notch journals such as Gastroenterology, JACC, Gut, and JEM, and he also served as the PI of several GI-cancer-related clinical trials. His major scientific achievements include the identification of a novel regulator for Wnt signaling and cancer stem cells, ASPM, and a master regulator of de novo treatment resistance in most cancers, N-CoR2. Dr. Tsai’s breakthrough findings along these lines of research have yielded a number of issued or pending global patents and he is now actively collaborating with academic and industrial sectors worldwide aiming at developing novel cancer therapeutics.

❖ Education:
1994-1997  Ph.D. in Biochemistry, National Taiwan University, Taipei, Taiwan
1991-1993  M.S. in Biochemistry, National Taiwan University, Taipei, Taiwan
1985-1989  B.S. in Chemistry, National Taiwan Normal University, Taipei, Taiwan
❖ Research Focus:
- Niche regulation of pluripotency in embryonic stem cell and somatic cancer
- Embryonic pluripotency and germ stem cell development
- Immuno-modulation and disease therapeutic potential of human placenta stem cells
❖ Honors/Awards:
2015  The International Top Journal Research Award of Taipei Medical University
2015  The Excellent Prize Research Award of Taipei Medical University 
2015  The Prize Oral Award, 2015 Taiwan Society For Stem Cell Research (2015 TSSCR),Taipei, Taiwan
2014   2014~2016 Stem Cell Highlighting Program Project, Ministry of Science Technology (MOST), Executive Yuan, Taiwan. 
2013   2013 Faculty Award of Taipei Medical University in Excellence of Teaching, Administration, and Research. 
2013   The First Prize Oral Award, 2013 TSRM, Annual Meeting of Taiwan Society for Reproductive Medicine, Taiwan
2012   2012~2015 Outstanding Young Scientist Research Grant, Ministry of ScienceTechnology (MOST), Executive Yuan, Taiwan
2012   2012~2015 Stem Cell Highlighting Program Project, Ministry of Science Technology (MOST), Executive Yuan, Taiwan. 
2012   2012 The Best Teacher Award, School of Medicine, Taipei Medical University, Taiwan
2011   The First Prize Award of Excellent Research, “Taipei Medical University, Taipei, Taiwan
2011   The Best Teacher Award, School of Medicine, Taipei Medical University, Taipei, Taiwan
2010   Faculty Award of Taipei Medical University in Teaching
2008   2008~2011 Stem Cell Highlighting Program Project, Ministry of Science Technology (MOST), Executive Yuan, Taiwan. 

❖ Research Field:
- HPV-infected lung tumorigenesis
- MicroRNA expression profile in colon and breast cancer
- The role of microRNA in HCV-infected hepatocellular carcinoma therapy
- Colorectal cancer research
- Pterygium pathogenesis 
❖ Education:
Ph.D. Institute of Medicine, Jan 2002,Chung Shan Medical University, Taiwan, R.O.C.
M.S. Institute of Toxicology, June 1998,Chung Shan Medical & Dental College, Taiwan, R.O.C.
B.S. Department of Medical Technology, June 1996,Chung Shan Medical & Dental College, Taiwan, R.O.C.
❖ Positon Helded:
8/2011~date  Professor & Director,Graduate Institute of Cancer Biology and Drug Discovery,Taipei Medical University
2/2009~2011/07  Professor, Institute of Medicine,Chung Shan Medical University, Taiwan, R.O.C.
12/2005~1/2009  Associate Professor, Institute of Medicine,Chung Shan Medical University, Taiwan, R.O.C.
8/2002~11/2005  Assistant Professor, Institute of Medicine,Chung Shan Medical University, Taiwan, R.O.C.
2/2002~7/2002  Postdoctoral fellow, Institute of Toxicology,Chung Shan Medical University, Taiwan, R.O.C.
❖ Honors:
2009/03/06~2009/03/09  The 17th Annual Meeting of Asian Society for Cardiovascular and Thoracic Surgery(Invitee Speaker; Young Scientist Award)
2009/07/06~2009/07/08  The 36th Annual Meeting of the Japanese Society of Toxicology(Young Scientist Award)
2010/06~2010/10  Department of Molecular Pharmacology, Beckman Research Institute, City of Hope, National Medical Center(Visiting Professor)
2015/05/03  Dr. Dong Dacheng Award of Excellent Basic Medical Cancer Research

❖ Research Interests:
Dr. Wang studies the molecular mechanisms involved in lung tumorigenesis. Her group investigates the etiological association of alterations in tumor suppressor genes and oncogenes with lung tumorigenesis. The alteration analyses include the following aspects: gene mutation and polymorphism, gene amplification and loss, hypermethylation of promoter, chromatin structure alteration of gene locus, mRNA alteration, and protein expression alteration. More recently, Dr. Wang has continued to do research on cancer genomics and epigenomics such as array comparative genomic hybridization, and genome-scanning approaches of DNA methylation and chromatin alteration profiles for identification of new genes critical to lung tumorigenesis. Several potential anti-cancer drugs also are developing in her laboratory.
❖ Education:
1983~1987  B.Sc.(Horticulture), Chinese Culture University
1988-1993   Ph.D.(Genetics), Michigan State University
❖ Positions and Employment:
1993~1995  Post-doctoral fellow, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
1995~1999  Associate Professor, Institute of Toxicology, Chung Shan Medical Univ., Taichung, Taiwan
1999~2006  Professor, Department of Life Science, National Taiwan Normal Univ., Taipei, Taiwan
2006~present  Distinguished Professor, Department of Pharmacology & Institute of Basic Medical Sciences & Institute of Clinical Medical Sciences, National Cheng Kung University, Tainan,Taiwan
❖ Awards:
2004, 2010, 2014  Outstanding research award of Ministry of Science and Technology, Taiwan
2007  Distinguished alumnus of Chinese Culture University, Taiwan
2007~2013  Research award of Cheng-Shin Medical Foundation, Taiwan
2008  Outstanding research award, Pharmacology Society, Taiwan
2010  Outstanding research award, College of Medicine, National Cheng Kung University, Taiwan
2013  Outstanding research award of Basic Research, The Chinese Oncology Society, Taiwan

❖ General Profile:
Upon completion of my doctorate in biochemistry at the National Taiwan University in 1994, I joined the faculty of the Graduate Institute of Biomedical Technology, Taipei Medical University, where I directed research combining basic genomics and breast cancer research with translational research. My major research interests are the molecular mechanisms of environmentally and chemically induced carcinogenesis, drug-induced apoptosis and cell cycle disruption. Recently, my research has focused on the analysis of the mechanisms involving nicotinic receptors in human breast cancer formation. These findings led to the development of powerful antitumor agents, and the cloning of a nicotinic receptor gene linked to breast cancer has led to investigation of this receptor as a potential therapeutic target for smoking-induced breast cancer and other cancers. I was voted chairman of the Translational Cancer Research Center at the Taipei Medical University in 2009. This work will further establish a translational research team in which basic and clinical researchers collaborate to focus on the mechanisms of breast cancer formation.
❖ Education:
1990–1994: Ph.D. (Biochemistry), National Taiwan University, College of Medicine, Taipei, Taiwan, Republic of China
❖ Professional Experience:
1994–1995 Postdoctoral Researcher, National Taiwan University, College of Medicine, Taipei, Taiwan, ROC
1995–2001 Associate Professor, Institute of Biomedical Technology, Taipei Medical College, Taipei, Taiwan, ROC
2001–2004 Professor, Institute of Biomedical Technology, Taipei Medical University, Taipei, Taiwan, ROC
2002–2004 Chairman, School of Medical Technology, Taipei Medical University, Taipei, Taiwan, ROC
2002–2004 Chairman, Graduate Institute of Biomedical Technology, Taipei Medical University, Taipei, Taiwan, ROC
2011–2011 Chairman, Translational Cancer Research Center, Taipei Medical University, Taipei, Taiwan, ROC
2014~         Distinguished professor, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University
2015~         Director, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University
❖ Awards and Honors:
- The Best Research Award of the Chinese Oncology Society: Prof. Tung Da-Cheng's The Best Research Award (2012).
- Excellent Research Award of the National Science Council (1995–1996, 1998–2002); Excellent Research Award of the Taipei Medical University (2009, 2011, 2012)
- Bronze Research Award, Taipei Medical University (2000–2001)
- Bronze Research Award, Taipei Medical University (2003)
- Excellence in Innovation of Teaching Methods, Taipei Medical University (2000)
- listed in Who's Who in Medicine and Healthcare (21^st edition, 2002–2007)
- listed in Who's Who in Science and Engineering (21^st edition, 2003–2007)
- listed in Who's Who in the World (21^st edition, 2003–2007)

❖ General Profile:
Shwu-Bin Lin, PhD, is professor of National Taiwan University, Department of Laboratory Sciences and Medical Biotechnology, and consultant of TRINEO Biotechnology Company. Dr. Lin’s research focuses on studying the efficacy of purified phytochemicals as anticancer or chemopreventive compound for pharmaceutical and neutraceutical innovation of folk medicinal plants. The research contents emphasize mechanistic study of the phytochemical’s effects on novel cellular signal transduction pathway or on known drug targets. Her research has helped translation of anticancer triterpenoid from Ganoderma to commercial products.

❖ Academic Degrees:
1964-1968  B.S. in Pharmacy, Kaohsiung Medical College
1969-1972  M.S. Pharmacological Institute, College of Medicine, National Taiwan University (NTUMC)
1973-1977  Ph.D. Pharmacological Institute, NTUMC
❖ Present Position:
1984-    Professor, Department of Pharmacology, NTUMC
❖ Professional Experiences:
1970-1973  Assistant, Department of Pharmacology, NTUMC
1973-1978  Lecturer, Department of Pharmacology, NTUMC
1979-1981  Research Associate (NIH Forgaty International Fellowship), Department of Physiology, College of Medicine, Wayne State University, Michigan, U.S.A.
1978-1984  Associate Professor, Department of Pharmacology, NTUMC
1988-1990  Chairman, Experimental Animal Center, NTUMC
1990-1996  Chairman, Department of Pharmacology, NTUMC
1996-1998  Team Leader, Drug Research and Development Group, NTUMC 
2010-2004  Associate Dean, Office for Research and Development, NTUMC
2003-2010  Chief Leader, National Science and Technology Program for Biotechnology and Pharmaceuticals (NSTPBP)
❖ Research Awards:
1985-1997 Outstanding Research Award, National Science Council
1988   Chong-Shan Research Award
1990   Distinguishing Achievement Award for Science and Technology, Executive Yuan
1994   Dr. Tsung-Ming Tu's Memorial Lecture Award
1994   Academic Award, Ministry of Education 
1996   Ho Chin-Tui Outstanding Award
2002   Lifu Academic Award for Chinese Medicine
2005   Outstanding Achievement Award in Science and Technology, Executive Yuan
2009   Dr. Tong Ta-Chun's Outstanding Basic Medical Research Award on Oncology
2010   Outstanding Achievement Award, Wang Ming-Ning Memorial Foundation
2011   National Professorship, Ministry of Education
2013   Professorship, National Taiwan University

❖ Research Intersts：
Cancer Biology, Medical Oncology, Hematology, Internal medicine
❖ Education:
Aug 2010~Jul 2011  Visiting Scientist, M.D. Anderson Cancer Center, Houston, TX, USA
Aug 2006~Jul 2007  Post-Doctoral Fellow, Institute of Biochemisty and Molecular Biology, National Yang Ming University, Taipei, Taiwan
Sep 2003~Jul 2006   Ph.D, Institure of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
Sep 1987~Jul 1994   M.D., Faculty of Medicine, National Yang Ming University, Taipei, Taiwan
❖ Academic Positions:
Mar 2015~present  Director, Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taiwan
Aug 2013~present  Professor, Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
Aug 2013~present  Adjunct Professor, Institute of Biotechnology in Medicine, Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
Aug 2014~present  Adjunct Research Fellow, Genomic Research Center, Academia Sinica, Taipei, Taiwan
Aug 2014~present  Director, Genomic Research Center, National Yang-Ming University, Taipei, Taiwan
Aug 2013~present  Director, Immunology Research Center, National Yang-Ming University, Taipei, Taiwan
Sep 2002~present   Attending Physician, Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taiwan
Dec 2012~Jul 2014   Adjunct Associate Research Fellow, Genomic Research Center, Academia Sinica, Taipei, Taiwan
Aug 2007~Jul 2013   Assistant Professor, Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
Aug 2002~Jan 2007   Instructor, Faculty of Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
❖ Honors and Awards:
2005: Scholar-in-Training Award, 97th American Association for Cancer Research
2005: Award of Best Research Project, Taiwan Society of Hematology
2006: Award of Distinguished Thesis, Taiwan Society of Hematology
2007: Award of the Best Research Project, 12th Taiwan Joint Cancer Conference
2008: Award of Distinguished Thesis, Tien-Te Lee Biomedical Foundation, Taiwan
2008: Ta-Yu Wu Memorial Award, National Science Council, Taiwan
2009: Award of Distinguished Thesis, Taiwan Society of Hematology
2009: Award of the Best Research Project, 14th Taiwan Joint Cancer Conference
2009: Dr. Ta-Cheng Tung Memorial Award for Basic Cancer Research, Chinese Oncology Society, Taiwan
2009: First prize of Distinguished Thesis, Taipei Veterans General Hospital
2010: Award of the Best Research Project, 15th Taiwan Joint Cancer Conference
2011: First prize of Distinguished Thesis, Taipei Veterans General Hospital
2011: Young Scientist Research Award, Tien-Te Lee Biomedical Foundation, Taiwan
2011: Award for Junior Research Investigator, Academia Sinica
2011：Distinguished research award, National Yang-Ming University
2012: Outstanding Research Award, National Science Council, Taiwan
2013: First prize of Distinguished Thesis, Taipei Veterans General Hospital
2013：Distinguished research award, National Yang-Ming University
2014: Third prize of Distinguished Thesis, Taipei Veterans General Hospital
2014：Excellent teaching award, National Yang-Ming University
2015：Chien-Tien Hsu Outstanding Cancer Research Award, The Chinese Oncology Society
2015：Bio-medical Technology, 13th Y. Z. Hsu Scientific Paper Award